Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2007 by Korea Otsuka Pharmaceutical Co.,Ltd..
Recruitment status was  Recruiting
Otsuka Pharmaceutical Co., Ltd.
Information provided by:
Korea Otsuka Pharmaceutical Co.,Ltd.
ClinicalTrials.gov Identifier:
First received: October 25, 2007
Last updated: NA
Last verified: October 2007
History: No changes posted
to survey oral mucositis after chemotherapy and Concurrent chemoradiotherapy in Korean cancer patients

Condition Intervention
Oral Mucositis
Other: no intervention study

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients

Further study details as provided by Korea Otsuka Pharmaceutical Co.,Ltd.:

Primary Outcome Measures:
  • incidence and severity of oral mucositis

Study Start Date: October 2007
Estimated Study Completion Date: March 2008

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients diagnosed with one cancer among head and neck cancer, esophageal cancer, breast cancer, colorectal cancer, gastric cancer, and non-small cell lung cancer, who are being treated or going to be treated as one between A and B A. Chemotherapy only B. Concurrent chemoradiotherapy

Exclusion Criteria:

  • Patients who are pregnant or breast feeding, absent from effective(medically proven) contraceptive method for females of childbearing potential
  • Patients with performance status of ECOG score is more than 3
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00549952

Contact: Yonghui Jeong 82-2-3465-3956 jeongyh@otsuka.co.kr
Contact: Boyoun Seo 82-2-3465-5485 byseo@otsuka.cokr

Korea, Republic of
Seoul National University hospital Recruiting
Seoul, Korea, Republic of, 110-744
Principal Investigator: Do-Youn Oh         
Sponsors and Collaborators
Korea Otsuka Pharmaceutical Co.,Ltd.
Otsuka Pharmaceutical Co., Ltd.
Principal Investigator: Do-Youn Oh, PhD Seoul National University Hospital
  More Information

ClinicalTrials.gov Identifier: NCT00549952     History of Changes
Other Study ID Numbers: 256-KOB-0701 
Study First Received: October 25, 2007
Last Updated: October 25, 2007
Health Authority: South Korea: Institutional Review Board

Additional relevant MeSH terms:
Digestive System Diseases
Gastrointestinal Diseases
Mouth Diseases
Stomatognathic Diseases

ClinicalTrials.gov processed this record on April 27, 2016